Skip to main content
Erschienen in: Cellular Oncology 5/2014

01.10.2014 | Original Paper

A novel saliva-based microRNA biomarker panel to detect head and neck cancers

verfasst von: Carolina Salazar, Rahul Nagadia, Pratibala Pandit, Justin Cooper-White, Nilanjana Banerjee, Nevenka Dimitrova, William B Coman, Chamindie Punyadeera

Erschienen in: Cellular Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

MicroRNAs (miRNAs) are known to play an important role in cancer development by post-transcriptionally affecting the expression of critical genes. The aims of this study were two-fold: (i) to develop a robust method to isolate miRNAs from small volumes of saliva and (ii) to develop a panel of saliva-based diagnostic biomarkers for the detection of head and neck squamous cell carcinoma (HNSCC).

Methods

Five differentially expressed miRNAs were selected from miScript™ miRNA microarray data generated using saliva from five HNSCC patients and five healthy controls. Their differential expression was subsequently confirmed by RT-qPCR using saliva samples from healthy controls (n = 56) and HNSCC patients (n = 56). These samples were divided into two different cohorts, i.e., a first confirmatory cohort (n = 21) and a second independent validation cohort (n = 35), to narrow down the miRNA diagnostic panel to three miRNAs: miR-9, miR-134 and miR-191. This diagnostic panel was independently validated using HNSCC miRNA expression data from The Cancer Genome Atlas (TCGA), encompassing 334 tumours and 39 adjacent normal tissues. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic capacity of the panel.

Results

On average 60 ng/μL miRNA was isolated from 200 μL of saliva. Overall a good correlation was observed between the microarray data and the RT-qPCR data. We found that miR-9 (P <0.0001), miR-134 (P <0.0001) and miR-191 (P <0.001) were differentially expressed between saliva from HNSCC patients and healthy controls, and that these miRNAs provided a good discriminative capacity with area under the curve (AUC) values of 0.85 (P <0.0001), 0.74 (P < 0.001) and 0.98 (P < 0.0001), respectively. In addition, we found that the salivary miRNA data showed a good correlation with the TCGA miRNA data, thereby providing an independent validation.

Conclusions

We show that we have developed a reliable method to isolate miRNAs from small volumes of saliva, and that the saliva-derived miRNAs miR-9, miR-134 and miR-191 may serve as novel biomarkers to reliably detect HNSCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat D. Chin, G.M. Boyle, S. Porceddu, D.R. Theile, P.G. Parsons, W.B. Coman, Head and neck cancer: past, present and future. Expert. Rev. Anticancer. Ther. 6, 1111–1118 (2006)PubMedCrossRef D. Chin, G.M. Boyle, S. Porceddu, D.R. Theile, P.G. Parsons, W.B. Coman, Head and neck cancer: past, present and future. Expert. Rev. Anticancer. Ther. 6, 1111–1118 (2006)PubMedCrossRef
2.
Zurück zum Zitat D. Weiss, C. Stockmann, K. Schrodter, C. Rudack, Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma. Cell. Oncol. 36, 213–224 (2013)CrossRef D. Weiss, C. Stockmann, K. Schrodter, C. Rudack, Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma. Cell. Oncol. 36, 213–224 (2013)CrossRef
3.
Zurück zum Zitat T. Nakaoka, A. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, Y. Ohmura, Y. Yamada, Y. Hosokawa, Y. Kazaoka, Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol. 37, 119–129 (2014)CrossRef T. Nakaoka, A. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, Y. Ohmura, Y. Yamada, Y. Hosokawa, Y. Kazaoka, Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol. 37, 119–129 (2014)CrossRef
4.
Zurück zum Zitat P.A. Wingo, T. Tong, S. Bolden, Cancer statistics for African Americans. CA Cancer J. Clin. 45, 8–30 (1995)PubMedCrossRef P.A. Wingo, T. Tong, S. Bolden, Cancer statistics for African Americans. CA Cancer J. Clin. 45, 8–30 (1995)PubMedCrossRef
6.
Zurück zum Zitat T. Pfaffe, J. Cooper-White, P. Beyerlein, K. Kostner, C. Punyadeera, Diagnostic potential of saliva: current state and future applications. Clin. Chem. 57, 675–687 (2011)PubMedCrossRef T. Pfaffe, J. Cooper-White, P. Beyerlein, K. Kostner, C. Punyadeera, Diagnostic potential of saliva: current state and future applications. Clin. Chem. 57, 675–687 (2011)PubMedCrossRef
7.
Zurück zum Zitat R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)CrossRef R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)CrossRef
8.
Zurück zum Zitat U.M. Bailey, C. Punyadeera, J.J. Cooper-White, B.L. Schulz, Analysis of the extreme diversity of salivary alpha-amylase isoforms generated by physiological proteolysis using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 911, 21–26 (2012)PubMedCrossRef U.M. Bailey, C. Punyadeera, J.J. Cooper-White, B.L. Schulz, Analysis of the extreme diversity of salivary alpha-amylase isoforms generated by physiological proteolysis using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 911, 21–26 (2012)PubMedCrossRef
9.
Zurück zum Zitat B.L. Schulz, J. Cooper-White, C.K. Punyadeera, Saliva proteome research: current status and future outlook. Crit. Rev. Biotechnol. 33, 246–59 (2012)PubMedCrossRef B.L. Schulz, J. Cooper-White, C.K. Punyadeera, Saliva proteome research: current status and future outlook. Crit. Rev. Biotechnol. 33, 246–59 (2012)PubMedCrossRef
10.
Zurück zum Zitat C. Punyadeera, P.D. Slowey, in Nanobiomaterials in clinical dentistry, ed. by K. Subramani, W. Ahmed, J.K. Hartsfield (William Andrew Publishing, Waltham, 2013), pp. 453–473CrossRef C. Punyadeera, P.D. Slowey, in Nanobiomaterials in clinical dentistry, ed. by K. Subramani, W. Ahmed, J.K. Hartsfield (William Andrew Publishing, Waltham, 2013), pp. 453–473CrossRef
12.
Zurück zum Zitat H. Fabryova, P. Celec, On the origin and diagnostic use of salivary RNA. Oral Dis. 20, 146–52 (2013)PubMedCrossRef H. Fabryova, P. Celec, On the origin and diagnostic use of salivary RNA. Oral Dis. 20, 146–52 (2013)PubMedCrossRef
13.
Zurück zum Zitat Y. Li, X. Zhou, M.A. St John, D.T. Wong, RNA profiling of cell-free saliva using microarray technology. J. Dent. Res. 83, 199–203 (2004)PubMedCrossRef Y. Li, X. Zhou, M.A. St John, D.T. Wong, RNA profiling of cell-free saliva using microarray technology. J. Dent. Res. 83, 199–203 (2004)PubMedCrossRef
14.
Zurück zum Zitat N.J. Park, H. Zhou, D. Elashoff, B.S. Henson, D.A. Kastratovic, E. Abemayor, D.T. Wong, Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15, 5473–5477 (2009)PubMedCrossRefPubMedCentral N.J. Park, H. Zhou, D. Elashoff, B.S. Henson, D.A. Kastratovic, E. Abemayor, D.T. Wong, Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15, 5473–5477 (2009)PubMedCrossRefPubMedCentral
15.
Zurück zum Zitat R.S. Patel, A. Jakymiw, B. Yao, B.A. Pauley, W.C. Carcamo, J. Katz, J.Q. Cheng, E.K. Chan, High resolution of microRNA signatures in human whole saliva. Arch. Oral Biol. 56, 1506–1513 (2011)PubMedCrossRefPubMedCentral R.S. Patel, A. Jakymiw, B. Yao, B.A. Pauley, W.C. Carcamo, J. Katz, J.Q. Cheng, E.K. Chan, High resolution of microRNA signatures in human whole saliva. Arch. Oral Biol. 56, 1506–1513 (2011)PubMedCrossRefPubMedCentral
17.
Zurück zum Zitat S. Babashah, M. Sadeghizadeh, M.R. Tavirani, S. Farivar, M. Soleimani, Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell. Oncol. 35, 317–334 (2012)CrossRef S. Babashah, M. Sadeghizadeh, M.R. Tavirani, S. Farivar, M. Soleimani, Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell. Oncol. 35, 317–334 (2012)CrossRef
18.
Zurück zum Zitat E. Yiannakopoulou, Targeting epigentic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents-implications for cancer treatment and chemoprevention. Cell. Oncol. 37, 167–178 (2014)CrossRef E. Yiannakopoulou, Targeting epigentic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents-implications for cancer treatment and chemoprevention. Cell. Oncol. 37, 167–178 (2014)CrossRef
19.
Zurück zum Zitat D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004)PubMedCrossRef D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004)PubMedCrossRef
20.
Zurück zum Zitat G.A. Calin, C.D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating, K. Rai, L. Rassenti, T. Kipps, M. Negrini, F. Bullrich, C.M. Croce, Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lympocytic leukemmia. Proc. Natl. Acad. Sci. U. S. A. 99, 15524–15529 (2002)PubMedCrossRefPubMedCentral G.A. Calin, C.D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating, K. Rai, L. Rassenti, T. Kipps, M. Negrini, F. Bullrich, C.M. Croce, Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lympocytic leukemmia. Proc. Natl. Acad. Sci. U. S. A. 99, 15524–15529 (2002)PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat D. Xiao, J. Ohlendorf, Y. Chen, D.D. Taylor, S.N. Rai, S. Waigel, W. Zacharias, H. Hao, K.M. McMasters, Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 7, e46874 (2012)PubMedCrossRefPubMedCentral D. Xiao, J. Ohlendorf, Y. Chen, D.D. Taylor, S.N. Rai, S. Waigel, W. Zacharias, H. Hao, K.M. McMasters, Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 7, e46874 (2012)PubMedCrossRefPubMedCentral
22.
Zurück zum Zitat R. Mohamed, J.L. Campbell, J. Cooper-White, G. Dimeski, C. Punyadeera, The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. Clin. Transl. Med. 1, 19 (2012)PubMedCrossRefPubMedCentral R. Mohamed, J.L. Campbell, J. Cooper-White, G. Dimeski, C. Punyadeera, The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. Clin. Transl. Med. 1, 19 (2012)PubMedCrossRefPubMedCentral
23.
24.
Zurück zum Zitat S.C. Sahu, microRNAs in: Toxicology and Medicine, 1st edn. (Wiley, 2013), pg 486 S.C. Sahu, microRNAs in: Toxicology and Medicine, 1st edn. (Wiley, 2013), pg 486
25.
Zurück zum Zitat S.A. Bustin, G.L. Shipley, J. Vandesompele, C.T. Wittwer, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611–622 (2009)PubMedCrossRef S.A. Bustin, G.L. Shipley, J. Vandesompele, C.T. Wittwer, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611–622 (2009)PubMedCrossRef
26.
Zurück zum Zitat A.L. Carvalho, W.-W. Jiang, Q. Claybourne, Y. Tokumaru, J. Lee, D. Goldenberg, E. Garrett-Mayer, S. Goodman, C.-s. Moon, W. Koch, W.H. Westra, C. Jeronimo, D. Sidransky, J.A. Califano, M.M. Kim, R. Henrique, Z. Zhang, M.O. Hoque, S. Chang, M. Brait, C.S. Nayak, Evaluation of promoter hypermethylation detection in body fluid as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin. Cancer Res. 14, 97–107 (2008)PubMedCrossRef A.L. Carvalho, W.-W. Jiang, Q. Claybourne, Y. Tokumaru, J. Lee, D. Goldenberg, E. Garrett-Mayer, S. Goodman, C.-s. Moon, W. Koch, W.H. Westra, C. Jeronimo, D. Sidransky, J.A. Califano, M.M. Kim, R. Henrique, Z. Zhang, M.O. Hoque, S. Chang, M. Brait, C.S. Nayak, Evaluation of promoter hypermethylation detection in body fluid as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin. Cancer Res. 14, 97–107 (2008)PubMedCrossRef
27.
Zurück zum Zitat A.K. El-Naggar, K. Hurr, J.G. Batsakis, M.A. Luna, H. Goepfert, V. Huff, Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res. 55, 2656–2659 (1995)PubMed A.K. El-Naggar, K. Hurr, J.G. Batsakis, M.A. Luna, H. Goepfert, V. Huff, Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res. 55, 2656–2659 (1995)PubMed
28.
Zurück zum Zitat M.F. Huang, Y.C. Chang, P.S. Liao, T.H. Huang, C.H. Tsay, M.Y. Chou, Loss of heterozygosity of p53 gene of oral cancer detected by exfoliative cytology. Oral Oncol. 35, 296–301 (1999)PubMedCrossRef M.F. Huang, Y.C. Chang, P.S. Liao, T.H. Huang, C.H. Tsay, M.Y. Chou, Loss of heterozygosity of p53 gene of oral cancer detected by exfoliative cytology. Oral Oncol. 35, 296–301 (1999)PubMedCrossRef
29.
Zurück zum Zitat A.K. El-Naggar, L. Mao, G. Staerkel, M.M. Coombes, S.L. Tucker, M.A. Luna, G.L. Clayman, S. Lippman, H. Goepfert, Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J. Mol. Diagn. 3, 164–170 (2001)PubMedCrossRefPubMedCentral A.K. El-Naggar, L. Mao, G. Staerkel, M.M. Coombes, S.L. Tucker, M.A. Luna, G.L. Clayman, S. Lippman, H. Goepfert, Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J. Mol. Diagn. 3, 164–170 (2001)PubMedCrossRefPubMedCentral
30.
Zurück zum Zitat K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−Delta Delta C(T)) Method. Methods 25, 402–408 (2001)PubMedCrossRef K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−Delta Delta C(T)) Method. Methods 25, 402–408 (2001)PubMedCrossRef
31.
Zurück zum Zitat L. Zhu, H. Chen, D. Zhou, D. Li, R. Bai, S. Zheng, W. Ge, MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med. Oncol. 29, 1037–1043 (2012)PubMedCrossRef L. Zhu, H. Chen, D. Zhou, D. Li, R. Bai, S. Zheng, W. Ge, MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med. Oncol. 29, 1037–1043 (2012)PubMedCrossRef
32.
Zurück zum Zitat L. Ma, F. Reinhardt, E. Pan, J. Soutschek, B. Bhat, E.G. Marcusson, J. Teruya-Feldstein, G.W. Bell, R.A. Weinberg, Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341–347 (2010)PubMedCrossRefPubMedCentral L. Ma, F. Reinhardt, E. Pan, J. Soutschek, B. Bhat, E.G. Marcusson, J. Teruya-Feldstein, G.W. Bell, R.A. Weinberg, Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341–347 (2010)PubMedCrossRefPubMedCentral
33.
Zurück zum Zitat A.B. Hui, A. Lin, W. Xu, L. Waldron, B. Perez-Ordonez, I. Weinreb, W. Shi, J. Bruce, S.H. Huang, B. O’Sullivan, J. Waldron, P. Gullane, J.C. Irish, K. Chan, F.F. Liu, Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin. Cancer Res. 19, 2154–2162 (2013)PubMedCrossRef A.B. Hui, A. Lin, W. Xu, L. Waldron, B. Perez-Ordonez, I. Weinreb, W. Shi, J. Bruce, S.H. Huang, B. O’Sullivan, J. Waldron, P. Gullane, J.C. Irish, K. Chan, F.F. Liu, Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin. Cancer Res. 19, 2154–2162 (2013)PubMedCrossRef
34.
Zurück zum Zitat K.-i. Kozaki, I. Imoto, S. Mogi, K. Omura, J. Inazawa, Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 68, 2094–2105 (2008)PubMedCrossRef K.-i. Kozaki, I. Imoto, S. Mogi, K. Omura, J. Inazawa, Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 68, 2094–2105 (2008)PubMedCrossRef
35.
Zurück zum Zitat Y. Khew-Goodall, G.J. Goodall, Myc-modulated miR-9 makes more metastases. Nat. Cell Biol. 12, 209–211 (2010)PubMed Y. Khew-Goodall, G.J. Goodall, Myc-modulated miR-9 makes more metastases. Nat. Cell Biol. 12, 209–211 (2010)PubMed
36.
Zurück zum Zitat S.C. Lin, W.G. Shen, C.J. Liu, MiR-134 expression is oncogenic for oral carcinoma. Oral Oncol. 47, S121–S121 (2011)CrossRef S.C. Lin, W.G. Shen, C.J. Liu, MiR-134 expression is oncogenic for oral carcinoma. Oral Oncol. 47, S121–S121 (2011)CrossRef
37.
Zurück zum Zitat C.-J. Liu, W.G. Shen, S.-Y. Peng, H.-W. Cheng, S.-Y. Kao, S.-C. Lin, K.-W. Chang, miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int. J. Cancer 134, 811–821 (2014)PubMedCrossRef C.-J. Liu, W.G. Shen, S.-Y. Peng, H.-W. Cheng, S.-Y. Kao, S.-C. Lin, K.-W. Chang, miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int. J. Cancer 134, 811–821 (2014)PubMedCrossRef
38.
Zurück zum Zitat E. Elyakim, E. Sitbon, A. Faerman, S. Tabak, E. Montia, L. Belanis, A. Dov, E.G. Marcusson, C.F. Bennett, A. Chajut, D. Cohen, N. Yerushalmi, hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 70, 8077–8087 (2010)PubMedCrossRef E. Elyakim, E. Sitbon, A. Faerman, S. Tabak, E. Montia, L. Belanis, A. Dov, E.G. Marcusson, C.F. Bennett, A. Chajut, D. Cohen, N. Yerushalmi, hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 70, 8077–8087 (2010)PubMedCrossRef
39.
Zurück zum Zitat S. Volinia, G.A. Calin, C.G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R.L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C.C. Harris, C.M. Croce, A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 103, 2257–2261 (2006)PubMedCrossRefPubMedCentral S. Volinia, G.A. Calin, C.G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R.L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C.C. Harris, C.M. Croce, A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 103, 2257–2261 (2006)PubMedCrossRefPubMedCentral
40.
Zurück zum Zitat C. Hebert, K. Norris, M.A. Scheper, N. Nikitakis, J.J. Sauk, High moility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 6, 5 (2007)PubMedCrossRefPubMedCentral C. Hebert, K. Norris, M.A. Scheper, N. Nikitakis, J.J. Sauk, High moility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 6, 5 (2007)PubMedCrossRefPubMedCentral
41.
Zurück zum Zitat E.V. Barker, N.K. Cervigne, P.P. Reis, R.S. Goswami, W. Xu, I. Weinreb, J.C. Irish, S. Kamel-Reid, microRNA evaluation of unknown primary lesions in the head and neck. Mol. Cancer 8, 127 (2009)PubMedCrossRefPubMedCentral E.V. Barker, N.K. Cervigne, P.P. Reis, R.S. Goswami, W. Xu, I. Weinreb, J.C. Irish, S. Kamel-Reid, microRNA evaluation of unknown primary lesions in the head and neck. Mol. Cancer 8, 127 (2009)PubMedCrossRefPubMedCentral
Metadaten
Titel
A novel saliva-based microRNA biomarker panel to detect head and neck cancers
verfasst von
Carolina Salazar
Rahul Nagadia
Pratibala Pandit
Justin Cooper-White
Nilanjana Banerjee
Nevenka Dimitrova
William B Coman
Chamindie Punyadeera
Publikationsdatum
01.10.2014
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 5/2014
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0188-2

Weitere Artikel der Ausgabe 5/2014

Cellular Oncology 5/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …